---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-237716"
form_type: "8-K"
ticker: "GH"
cik: "0001576280"
company_name: "Guardant Health, Inc."
filed_at: "2021-08-05T23:59:59+00:00"
generated_at: "2026-06-29T21:39:45.086821+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Guardant Health names co-CEOs, splits oncology and screening groups; adds Meghan Joyce to board

## Summary
- Helmy Eltoukhy and AmirAli Talasaz appointed co-CEOs effective Aug 5, 2021; Eltoukhy becomes Chairman.
- Talasaz steps down as COO but remains President; Eltoukhy leads oncology, Talasaz screening division.
- Meghan Joyce, Oscar Health COO/EVP, named independent director; joined audit and compensation committees.
- Joyce received initial stock option and RSU awards each valued at $362,500 under director compensation plan.
- Company plans blood-based screening LDT launch in 2022 and cites recent launches of Reveal, TissueNext, Response.

## SEC filing metadata
- accession: 0001193125-21-237716
- form_type: 8-K
- ticker: GH
- cik: 0001576280
- company_name: Guardant Health, Inc.
- filed_at: 2021-08-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1576280/000119312521237716/0001193125-21-237716-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1576280/000119312521237716/d212126d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-237716
- JSON: https://secwatch.observer/filing/0001193125-21-237716.json
- Plain text: https://secwatch.observer/filing/0001193125-21-237716.txt

## Key facts
- Executive change
  Meghan Joyce was appointed as Class II director at Guardant Health, Inc..
  - Action: appointed
  - Role: Class II director
  source text: the Board increased the number of directors on the Board to eight and appointed Meghan Joyce as a Class II director
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000119312521237716/0001193125-21-237716-index.htm
- Executive change
  Helmy Eltoukhy changed role as Co-Chief Executive Officer at Guardant Health, Inc..
  - Action: changed title
  - Role: Co-Chief Executive Officer
  source text: changed the title of Helmy Eltoukhy, the Company’s current Chief Executive Officer, to the Company’s Co-CEO
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000119312521237716/0001193125-21-237716-index.htm
- Executive change
  AmirAli Talasaz resigned as Chief Operating Officer at Guardant Health, Inc..
  - Action: resigned
  - Role: Chief Operating Officer
  source text: Dr. Talasaz has also announced his intent to resign from his position as Chief Operating Officer of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000119312521237716/0001193125-21-237716-index.htm
- Executive change
  AmirAli Talasaz was appointed as Co-Chief Executive Officer at Guardant Health, Inc..
  - Action: appointed
  - Role: Co-Chief Executive Officer
  source text: the Company appointed AmirAli Talasaz as the Company’s Co-CEO
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000119312521237716/0001193125-21-237716-index.htm
- Executive change
  AmirAli Talasaz resigned as Chairperson of the Board at Guardant Health, Inc..
  - Action: resigned
  - Role: Chairperson of the Board
  source text: Dr. Talasaz announced his intent to resign from his position as Chairperson of the Board
  evidence_url: https://www.sec.gov/Archives/edgar/data/1576280/000119312521237716/0001193125-21-237716-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.